Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 31 - 54 of 54

Full-Text Articles in Medicine and Health Sciences

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava Sep 2009

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava Sep 2009

Should Schizoaffective Disorder Be Dropped From Dsm V, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava Aug 2009

Coping With Clinical Challenges Of Risk-Assessment, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson Aug 2009

Coping With Clinical Challenges Of Risk Assessment: Towards A New Comprehensive Instrument, Amresh Srivastava, Charles Nelson

Amresh Srivastava

No abstract provided.


Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava Aug 2009

Catatonia Yesterday, Today, Tomorrow, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Schizophrenia: General Findings And Current Status, Amresh Srivastava Aug 2009

Schizophrenia: General Findings And Current Status, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Relapse Prevention In Schizophrenia, Amresh Srivastava Aug 2009

Relapse Prevention In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava Jul 2009

Cognition As An Outcome Measure In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava Jul 2009

Mood Symptoms As Comorbidity In Schizophrenia, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt Jul 2009

Differential Characteristics Of “Good Outcome Schizophrenia” In A Long-Term Ten Years Study, Mumbai, India, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Amresh Srivastava

No abstract provided.


Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson Jul 2009

Coping Up Challenges Of Risk Assessment: Towards A New Scale: Sis-Map, Amresh Srivastava, Charles Nelson

Amresh Srivastava

No abstract provided.


Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt Jul 2009

Outcome In Schizophrenia: How Good Is "Good Outcome" Schizophrenia In Long-Term In Developing Countries, Amresh Srivastava, Meghan Thakar, Nilesh Shah, Larry Stitt

Amresh Srivastava

No abstract provided.


Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava Jul 2009

Complexity And Limitations Of Stress-Endocrine Research In Mental Health, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava Jul 2009

Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 1), Amresh Srivastava

Amresh Srivastava

No abstract provided.


Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava Jul 2009

Atypical Antipsychotics And Cognitive Enhancement In Schizophrenia: The Current Status, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava Jul 2009

Interface Of Cannabis And Early Psychosis--Priorities In Research And Service Development, Amresh Srivastava

Amresh Srivastava

Introduction: cannabis continues to affect mental health. Its abuse is on rise globally. In Canada a rise by 30% in last ten years has been observed in high school students. Interrelationship of cannabis with psychosis and schizophrenia is a complex one. Cannabis is highly comorbid with psychosis, & related to functional disability and outcome. It poses several challenges in understanding causal relationship for comorbidity, underlying neurochemical basis and specifics of service development. Prevalence of Cannabis varies from 20 to 50% early psychosis. Objective of this paper is to review available literature to identify challenges for newer targets of research and …


Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava Jul 2009

Identifying Schizophrenia: Paradigm Shift ‘The Uhr Research’, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava Jul 2009

Selecting Antidepressant Drugs For Management Of Depression In Primary Care (Part 2), Amresh Srivastava

Amresh Srivastava

No abstract provided.


Assessment In Crisis, Amresh Srivastava Jul 2009

Assessment In Crisis, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Switching And Selecting Atypical Antipsychotic Drugs: Quetiapine, Amresh Srivastava Jul 2009

Switching And Selecting Atypical Antipsychotic Drugs: Quetiapine, Amresh Srivastava

Amresh Srivastava

No abstract provided.


Tautology And Coercion In Assertive Community Treatment (Act): The "Treatment Effect" Of Assertive Community Treatment Deconstructed., Tomi Gomory Dec 2003

Tautology And Coercion In Assertive Community Treatment (Act): The "Treatment Effect" Of Assertive Community Treatment Deconstructed., Tomi Gomory

Tomi Gomory

Assertive Community Treatment (ACT) has been identified as one of only six evidence-based practices for the severely mentally ill by federal, private foundation, and professional mental health experts. This article reviews the research of the inventors of ACT (the Madison Wisconsin ACT group) because their model is the criterion for all ACT replications. The focus is on the well known, but mysterious “disappearance” of ACT effect when ACT “interventions” cease. The analysis concludes provocatively that there is no ACT clinical effect in the first place. What actually is measured by these researchers and claimed incorrectly as “clinical” treatment effect is …


The Origins Of Coercion In Assertive Community Treatment: A Review Of Early Publications From The Special Treatment Unit Of Mendota State Hospital., Tomi Gomory Jan 2002

The Origins Of Coercion In Assertive Community Treatment: A Review Of Early Publications From The Special Treatment Unit Of Mendota State Hospital., Tomi Gomory

Tomi Gomory

This article argues that Assertive Community Treatment (ACT) is fundamentally and historically based on the uncritical but societally well accepted view that medically justified coercion (punishment or unwanted treatment) is therapeutic. It documents this claim by reviewing the early professional history and the resultant publications of the inventors of ACT (originally known as Training in Community Living), consisting of psychiatrists, social workers, and psychologists who trained and worked during the 1960s through the 1980s, at Mendota State Hospital (eventually renamed Mendota Mental Health Institute) in Wisconsin.


Why I Am A Psychiatric Scientist, Kevin J. Black Dec 1995

Why I Am A Psychiatric Scientist, Kevin J. Black

Kevin J. Black, MD

No abstract provided.


Seizure Threshold In Electroconvulsive Therapy: I. Initial Seizure Threshold, C. Edward Coffey, Joseph Lucke, Richard D. Weiner, Andrew D. Krystal, Michael Aque Dec 1994

Seizure Threshold In Electroconvulsive Therapy: I. Initial Seizure Threshold, C. Edward Coffey, Joseph Lucke, Richard D. Weiner, Andrew D. Krystal, Michael Aque

Richard R Weiner

We measured initial seizure threshold by means of a structured stimulus dosage titration procedure in a clinical sample of 111 depressed patients undergoing brief-pulse, constantcurrent electroconvulsive therapy (ECT). Initial seizure threshold was approximately 60 millicoumbs (mc) (10 Joules) on average, but varied widely (6-fold) across patients. Initial seizure threshold was predicted by four variables: electrode placement (higher with bilateral), gender (higher in men), age (higher with increasing age), and dynamic impedance (inverse relationship). Use of neuroleptic medication was associated with a lower seizure threshold. EEG seizure duration was inversely related to initial seizure threshold, but no other relations with seizure …